SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.

NEW YORK, Aug. 8, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT), in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE). Under the terms of the merger agreement, the Company's shareholders will receive $68.50 in cash for each share of Global Blood common stock owned. The transaction is valued at approximately $5.4 billion.

Read more at prnewswire.com